Dec 17 2024 15 mins
At the 2024 edition of the Biomanufacturing World Summit series we sat down with Hari Pujar of Tessera Therapeutics and Flagship Pioneering to offer a concise but still in-depth look at the present and future of biopharmaceutical manufacturing, especially as it relates to Advanced Therapy Medicinal Products (ATMPs). Incredible progress has been made and is being made, but of course there are bottlenecks to be addressed as the industry grows, and as these new treatments become commercially available, the issue of cost comes into sharp focus. Where does the industry find itself today, and what are its plans for tomorrow? Give this interview a listen for a terrific window into the state of an industry on the cusp of an incredibly bright future.
--
Hari Pujar
Chief Operating Officer & Operating Partner
Tessera Therapeutics & Flagship Pioneering
Hari is a biopharmaceutical executive with experience in vaccine, biologics, mRNA, small molecule, gene therapy modalities, with a passion for value creation. He has enterprise-wide experience including platform and product development, cGMP manufacturing, and commercial, with geographies spanning North and South America, Europe, and Asia.